The review found no eligible studies for this question.
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during treatment (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids may leads to lower deep vein thrombosis during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in pulmonary embolism during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).
Higher‐dose heparin showed no clear difference in VTE compared with standard‐dose heparin (low certainty).
Higher‐dose heparin showed no clear difference in major bleeding compared with standard‐dose heparin (low certainty).
It is very uncertain whether higher‐dose heparin changes PE compared with standard‐dose heparin (very low certainty).
It is very uncertain whether higher‐dose heparin changes DVT compared with standard‐dose heparin (very low certainty).
It is very uncertain whether higher‐dose heparin changes adverse events (thrombocytopenia) compared with standard‐dose heparin (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.